Blincyto

Chemical Nameblinatumomab
Dosage FormInjection (intravenous; 35 mcg)
Drug ClassAntineoplastics
SystemBlood
CompanyAmgen
Approval Year2014

Indication

  • For the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
  • For the treatment of adults and children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Last updated on 8/16/2022

More on this drug: Clinical Trials

Document TitleYearSource
Blincyto (blinatumomab) Prescribing Information.2022Amgen Inc., Thousand Oaks, California
Document TitleYearSource
Acute lymphoblastic leukemia in adults.2022Alberta Health Services
Acute Lymphoblastic Leukemia, Version 2.2021.2021Journal of the National Comprehensive Cancer Network

Have we missed a study, or would you like to comment on a study?